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Background: The process of gastric carcinogenesis still remains to be elucidated. The identification of genes related to
this process may help to reduce mortality rates through early diagnosis and the development of new anticancer
therapies. Nucleophosmin 1 (NPM1) acts in ribosome biogenesis, centrosome duplication, maintenance of genomic
stability, and embryonic development. Recently, NPM1 has been implicated in the tumorigenesis processes. Here, we
evaluated NPM1 gene and protein expression in gastric tumors and in corresponding non-neoplastic gastric samples.
Methods: NPM1 protein expression was determined by Western blot in 17 pairs of gastric tumors and corresponding
non-neoplastic gastric tissue. The protein immunoreactivity was observed in 12 tumor samples. mRNA expression was
evaluated by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in 22 pairs of gastric tumors and in
matched non-neoplastic gastric tissue.
Results: NPM1 protein expression was significantly reduced in gastric cancer samples compared to matched
non-neoplastic gastric samples (P = 0.019). The protein level of NPM1 was reduced at least 1.5-fold in 35% of tumors
compared to paired non-neoplastic gastric tissue. However, NPM1 immunoreactivity was detected in neoplastic and
non-neoplastic cells, including in intestinal metaplastic, gastritis and inflammatory cells. NPM1 was mainly expressed in
nucleus and nucleolus subcellular compartments. The staining intensity and the percentage of immunoreactive cells
varied among the studied cases. The NPM1 mRNA level was reduced at least 1.5-fold in 45.5% of samples and increased
in 27.3% of samples. An inverse correlation between protein and mRNA expression was detected (r = -0.509, P = 0.037).
Intestinal-type gastric cancer presented higher mRNA levels than diffuse-type (P = 0.026). However, reduced NPM1
protein expression was associated with intestinal-type gastric cancer compared to matched non-neoplastic
gastric samples (P = 0.018). In addition, tumors from patients with known distant metastasis presented reduced NPM1
protein levels compared to tumors from patients without distant metastasis (P < 0.001).
Conclusion: Although the expression of NPM1 is heterogeneous in gastric tumors, our results suggest that NPM1
down-regulation may have a role in gastric carcinogenesis and may help in the selection of anticancer treatment
strategies.
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Gastric cancer (GC) is the fourth most common cancer
and the second leading cause of cancer-related death
worldwide [1]. Although this neoplasia is a serious pub-
lic health problem due to its high incidence and mortal-
ity, little is known about the molecular events involved
in gastric carcinogenesis.
Our group recently performed a proteomic analysis
aiming to identify proteins with a role in gastric car-
cinogenesis [2]. In this study, we observed reduced ex-
pression of nucleophosmin 1 (NPM1, also known as
B23, numatrin and NO38) in several gastric tumors
compared to non-neoplastic gastric samples by two-
dimensional electrophoresis and mass spectrometry.
NPM1 is a nucleolar phosphoprotein that shuttles con-
tinuously between the nucleus and the cytoplasm
(see review [3]). NPM1 function is not completely
known. NPM1 is a member of the nucleoplasmin fam-
ily of histone chaperones that favor DNA-histone and
nucleosome assembly in vitro and also interact with a
wide range of unfolded proteins, inducing proper fold-
ing in the active state [4]. These multifunctional pro-
teins act in ribosome biogenesis [5], centrosome
duplication [6,7], maintenance of genomic stability,
and embryonic development [8].
Not surprisingly, NPM1 has been implicated in
tumorigenesis processes. NPM1 overexpression was
described in solid tumors of diverse histological ori-
gins, including astrocytomas [9], as well as colon [10],
hepatocellular [11], bladder [12], breast [13], ovarian
[14] and prostate [15] carcinomas. Deletions and
chromosomal translocations involving the NPM1 locus
(5q35) were described in hematological malignancies
(see reviews [16,17]) and lung cancer [18]. Mutations
of NPM1 were also described in hematological malig-
nancies, and it has been suggested that NPM1-mu-
tated acute myeloid leukemia is a distinct leukemia
entity [19].
NPM1 seems to play a role as both a tumor suppres-
sor and an oncogene. For its tumor suppressor activity,
NPM1 seems to act directly and indirectly on the regu-
lation of p53 [3]. On the other hand, NPM1 is also in-
volved in transcriptional activation of some oncogenes,
such as MYC [20]. Therefore, NPM1 overexpression
leads to increased cell growth and proliferation and in-
hibits differentiation and apoptosis [3].
To our knowledge, only two studies have evaluated
NPM1 mRNA expression in a small set of human pri-
mary GC [21,22]. Thus, the role of NPM1 in gastric
carcinogenesis remains to be elucidated. In the present
study, we analyzed NPM1 mRNA and protein expres-
sion in GC and matched non-neoplastic gastric sam-
ples. We also evaluated the possible associations
between NPM1 and clinicopathological characteristics.Methods
Tissue samples
NPM1 mRNA expression was evaluated in 22 pairs of
GC samples and matched non-neoplastic gastric tissue
(>5 cm from the edge of the tumor). In 17 pairs of these
GC samples and corresponding non-neoplastic gastric
tissue, the protein expression was also evaluated. The
protein immunoreactivity was assessed in 12 tumors.
All the gastric samples were obtained from patients
who underwent gastrectomy for GC at João de Barros
Barreto University Hospital (HUJBB) in the State of
Pará, Northern Brazil, during the period from 2006 to
2010. Informed consent with approval of the ethics com-
mittee of HUJBB was obtained. All patients had negative
histories of exposure to either chemotherapy or radio-
therapy before surgery, and there was no co-occurrence
of other diagnosed cancers.
Part of the dissected tumor samples was formalin-
fixed and paraffin embedded (FFPE). Sections of FFPE
tissue were stained with hematoxylin-eosin for histo-
logical evaluation or used for immunohistochemistry
analysis (IHC). The other part of tumors and the paired
non-neoplastic tissue specimens were immediately cut
from resected stomachs, frozen in liquid nitrogen and
kept at -80°C until protein and nucleic acid extraction.
Table 1 shows the clinicopathological characteristics of
the GC samples. All samples were classified according to
Laurén [23], and tumors were staged using standard cri-
teria by TNM staging [24]. The presence of H. pylori, a
class I carcinogen, in GC and non-neoplastic samples
was detected by PCR assay. PCR for the urease gene
[25] and for the H. pylori virulence factor cytotoxin-
associated gene A (CagA) [26] was performed as previ-
ously reported using the DNA purified simultaneously
with the proteins and the mRNA. All reactions were per-
formed in duplicate. In each PCR experiment, positive
and negative controls were included. A sample was con-
sidered positive if a clear and visible band was observed
on the electrophoresis gel (2% agarose gel). In our sample,
all GC and non-neoplastic samples presented H. pylori
infection.
Protein and mRNA purification
Total protein and mRNA were simultaneously isolated
from the gastric tissue samples using the AllPrep DNA/
RNA/Protein Kit (Qiagen, Germany) according to the
manufacturer's instructions. The protein pellet was dis-
solved in a buffer containing 7 M urea, 2 M thiourea,
4% 3-[(3-cholamidopropyl) dimethylammonio]-1-propa-
nesulfonate (CHAPS), 50 mM dithiothreitol (DTT), 1%
Protease Inhibitor Cocktail (Sigma) and 0.5% each of
Phosphatase Inhibitor Cocktails 1 and 2 (Sigma-Aldrich,
USA). The protein concentration was determined by
the Bradford method (Sigma-Aldrich, USA). The RNA
Table 1 Clinicopathological characteristics NPM1 expression in gastric cancer samples
NPM1 protein NPM1 mRNA
Variable N Ratio T/N (Mean ± SD) P value N RQ (Mean ± SD) P value
Gender
Male 8 0.81 ± 0.36 0.431 12 2.47 ± 3.86 0.657
Female 9 0.67 ± 0.39 10 1.76 ± 3.43
Onset (years)
< 45 5 0.73 ± 0.48 0.973 7 0.95 ± 0.89 0.298
≥ 45 12 0.74 ± 0.34 15 2.70 ± 4.25
Tumor location
Cardia 2 0.87 ± 0.04 0.601 2 0.17 ± 0.19 0.429
Non-cardia 15 0.72 ± 0.39 20 2.34 ± 3.73
Histological subtype
Diffuse-type 4 0.97 ± 0.25 0.159 6 0.33 ± 0.28 0.026*
Intestinal-type 13 0.66 ± 0.38 16 2.83 ± 4.04
Differentiation
Moderately differentiated 8 0.72 ± 0.38 0.492 10 2.84 ± 4.14 0.990
Poorly differentiated 5 0.57 ± 0.40 6 2.81 ± 4.26
Stage
Early 4 0.66 ± 0.31 0.675 4 1.02 ± 1.05 0.472
Advanced 13 0.76 ± 0.40 17 2.54 ±4 .01
Tumor invasion
T1/T2 7 0.78 ± 0.27 0.672 9 1.61 ± 1.63 0.502
T3/T4 10 0.70 ± 0.44 12 2.73 ± 4.67
Lymph node metastasis
Absent 6 0.78 ± 0.30 0.757 7 1.48 ± 1.82 0.509
Present 11 0.71 ± 0.42 14 2.63 ± 4.31
Distant metastasis
Unknown/absent 14 0.86 ± 0.26 < 0.001a 18 1.21 ± 1.29 0.220
Present 3 0.15 ± 0.20 3 8.49 ± 7.18
T, tumor sample; N, matched non-neoplastic sample; SD, standard deviation; RQ, relative quantification – gastric tumor samples normalized by matched non-
neoplastic sample. *Differentially expressed between groups, P <0.05, using t-test for independent samples.
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Drop spectrophotometer (Kisker, Germany), and the RNA
integrity was determined by gel electrophoresis.
NPM1 protein expression by Western blot
Reduced protein (20 μg) from each sample was sepa-
rated on a 12.5% homogeneous SDS-PAGE gel and
electro-blotted to a polyvinylidene difluoride (PVDF)
membrane (Hybond-P, GE Healthcare, USA). The PVDF
membrane was blocked with phosphate-buffered saline
containing 0.1% Tween 20 and 5% low fat milk and incu-
bated overnight at 4°C with anti-NPM1 (FC-61991, 1:500,
Invitrogen, USA) and anti-β-Actin antibodies (ACTB;
Ac-74, 1:3000, Sigma-Aldrich, USA). After extensive wash-
ing, the PVDF membrane was incubated with a peroxidase-
conjugated secondary antibody for 1 hour at room
temperature. Immunoreactive bands were visualizedusing Western blotting Luminol reagent, and the images
were acquired using an ImageQuant 350 digital image
system (GE Healthcare, Sweden). ImageJ 1.43u software
(National Institutes of Health, USA) was used for gel
band quantitative densitometric analysis. ACTB was
used as a loading reference control. In each experiment,
tumor and matched non-neoplastic samples were applied
to the same gel. One of the non-neoplastic samples (refe-
rence) was applied to all gels to allow comparison among
different experiments.
NPM1 immunoreactivity by IHC
Paraffin sections from 12 different tumor samples were
subjected to IHC. Tumor tissue sections (3 or 4 mm-
thick) were deparaffinized in xylene and rehydrated in a
graded series of ethanol. After heat-induced epitope re-
trieval, the tissue sections were incubated with primary
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Neomarkes, USA). A universal peroxidase-conjugated
secondary antibody kit (LSAB System, DakoCytomation,
USA) was used for the detection system. We used 3.30-
diamino-benzidine/H2O2 (Dakocytomation, Denmark)
as the chromogen and hematoxylin as the counterstain.
Negative controls in which the primary antibody was re-
placed by bovine serum albumin (BSA) 5% in phosphate-
buffered saline (PBS) were performed in all series, and
sections of normal human amygdala tissue were used as
positive controls.
The slides were viewed by light microscopy using
a Nikon Eclipse E600 microscope (Nikon, NY, USA)
equipped with a digital camera Nikon DSM1200F (Nikon,
NY, USA). The nonstained region (white region) was se-
lected and set as background. Any staining was considered
to be a positive result, irrespective of intensity. An arbi-
trary semiquantitative score was developed to quantify
NPM1 immunoreactivity, as follows: 0, from negative to
minimal staining (< 10% of cells); 1+, for those tumors
showing a weak staining and over 10% of cells; 2+, for
those tumors presenting a moderate staining and over
10% of cells; and 3+, for those tumors presenting a
strong staining and over 10% of cells.
NPM1 mRNA expression by reverse transcription
quantitative polymerase chain reaction (qRT-PCR)
First, complementary DNA was synthesized using the
High-Capacity cDNA Archive kit (Applied Biosystems,
Poland) according to the manufacturer’s protocol. All
real-time RT-qPCR reactions were performed in tripli-
cate for both the target gene (NPM1: Hs01576587_g1,
Applied Biosystems, USA) and the internal control
(ACTB: Hs03023943_g1, Applied Biosystems, USA). The
relative quantification (RQ) of the gene expression was
calculated according to Pfaffl method [27]. A non-
neoplastic gastric tissue was designed as a calibrator for
all samples for the comparison between neoplastic and
non-neoplastic samples. In addition, the non-neoplastic
gastric tissue sample was designated as a calibrator for
each paired tumor for clinicopathological analysis.
Statistical analysis
Gene and protein expression data are shown as mean ±
standard deviation (SD) for each group. We first evalu-
ated the normal distribution of all data using the
Shapiro-Wilk normality test to determine the subse-
quent use of appropriate tests for statistical comparison.
NPM1 mRNA levels were not normally distributed and
were transformed (z-score) for analysis such that they
followed a normal distribution. Paired t-tests were per-
formed to compare the mean NPM1 expression between
non-neoplastic and tumor samples. The associations be-
tween the clinicopathological parameters and the meanNPM1 mRNA and protein expression were assessed
using t-tests for independent samples. The possible asso-
ciations between NPM1 immunoreactivity and clinico-
pathological parameters were assessed by Fisher’s exact
test. The correlation between NPM1 immunoreactivity
and mRNA or protein expression by Western blot was
analyzed by Spearman’s rank correlation test. The correl-
ation between NPM1 mRNA and protein expression by
Western blot was analyzed by Pearson’s test. For the
analyses using the t-test for independent samples and
the Pearson’s test, the NPM1 expression in tumor sam-
ples was calibrated by their matched non-neoplastic
counterpart. In all analyses, P < 0.05 was considered
significant.
Results
NPM1 protein expression was significantly reduced in
GC samples compared to matched non-neoplastic gastric
samples (0.99 ± 0.54 vs 1.39 ± 0.39, values relative to the
reference sample; P = 0.019, by paired t-test; Figure 1A).
The protein level of NPM1 was reduced at least 1.5-fold
(50% decrease in the expression) in 35% of GC samples,
and no tumor presented an increase in expression of 50%
compared to their paired non-neoplastic gastric tissue
(Figure 1B and 1C).
In all cases, the NPM1 immunoreactivity was detected
in neoplastic and non-neoplastic cells, including in in-
testinal metaplastic, gastritis and inflammatory cells
(Figure 2A-H). NPM1 was mainly expressed in nucleus
and nucleolus. Only one case presented cytoplasmatic
staining in the parietal cells (Figure 2B). The staining in-
tensity and the percentage of immunoreactive cells varied
among the studied cases (Table 2). In nuclei of tumor
cells, NPM1 immunoreactivity score ranged from 0 to 2,
with 41.7% cases presenting score 0. In nucleoli of tumor
cells, 5 of 12 cases (41.7%) presented score 0 and 7 of 12
(58.3%) presented score 2. The score of NPM1 immunore-
activity in the nucleoli of tumor cells was inversely cor-
related with the protein expression by Western blot
(r = -0.693, p = 0.039; by Spearman’s correlation).
The NPM1 mRNA expression did not differ between
GC and matched non-neoplastic gastric samples (0.29 ±
0.41 vs 0.39 ± 0.42, values relative to a calibrator non-
neoplastic sample; P = 0.33, by paired t-test; Figure 1D).
The NPM1 mRNA level was reduced at least 1.5-fold
in 45.5% of samples and increased in 27.3% of samples
(Figure 1E). A moderate inverse correlation was ob-
served between the relative quantifications of NPM1
protein and mRNA levels (r = -0.509; P = 0.037, by
Pearson’s correlation; Figure 1F).
The intestinal-type GC presented higher NPM1 mRNA
levels than diffuse-type GC (P = 0.026, by t-test; Table 1).
The mRNA expression was at least 50% reduced in all
diffuse-type. In the intestinal-type, the mRNA expression
Figure 1 Expression of NPM1 in gastric samples. (A) protein expression normalized by ACTB and calibrated by the level of a reference
sample; (B) the ratio of NPM1 protein expression between tumor and matched non-neoplastic samples; (C) Western blot using anti-NPM1 and
anti-ACTB antibodies in representative gastric tumors and their matched non-neoplastic counterparts; (D) mRNA expression normalized by ACTB
and calibrated by a non-neoplastic gastric tissue; (E) relative quantification of NPM1 mRNA expression, in which gastric tumors samples were
calibrated by the matched non-neoplastic tissue; (F) relationship between the relative quantification of NPM1 protein and mRNA levels, in which
non-neoplastic samples were used as reference for each matched tumor. T: tumor samples; N: non-neoplastic samples; RQ: Relative quantification.
*Reference sample in Western blot gels.
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in 37.5% in relation to their matched non-neoplastic
counterpart. On the other hand, the NPM1 protein level
did not differ between diffuse-type and intestinal-type GC.
However, intestinal-type GC presented a significant reduc-
tion of NPM1 protein expression compared to matched
non-neoplastic gastric samples (0.94 ± 0.58 vs 1.41 ± 0.42,
P = 0.018, by paired t-test). In addition, the protein level of
NPM1 was reduced at least 1.5-fold in 46.2% of intestinal-
type GC and in no case of diffuse-type GC.
Tumors from patients with known distant metastasis
showed reduced NPM1 protein expression compared to
tumors from patients without distant metastasis (P <
0.001, by t-test; Table 1). No association between NPM1
expression and any other clinicopathological characteris-
tics was found.
Discussion
NPM1 is a multifunctional protein. The first proposed role
of NPM1 was in the regulation of cell growth, proliferation
and transformation because its expression increases in
response to mitogenic stimuli and is up-regulated in
highly proliferative and malignant cells. However, se-
veral recent studies have demonstrated that NPM1 has
both proliferative and growth-suppressive roles in the
cell (see review [3]).In the present study, NPM1 protein expression was sig-
nificantly down-regulated in GC, which supports its role
as a tumor suppressor. One NPM1 target is cyclin-
dependent kinase inhibitor 2A (CDKNA2) alternate read-
ing frame protein (ARF; also known as p14ARF in
humans, and p19Arf in the mouse). ARF protein is in-
volved in cell-cycle arrest and apoptotic processes through
inhibition of MDM2 (E3 ubiquitin-protein ligase, a nega-
tive regulator of p53) and, therefore, stabilization of p53
[28]. NPM1 acts in the stabilization of ARF within the nu-
cleolus by protecting it from both proteasome-dependent
and proteasome-independent degradation. It has been
suggested that NPM1 loss of function could lead to an ac-
celeration of tumorigenesis owing to the destabilization
and inactivation of ARF, which is known to inhibit cell
proliferation through both p53-dependent and p53-
independent mechanisms [3,29], in agreement with a po-
tential tumor-suppressor role for NPM1.
The down-regulation of NPM1 was associated with
known distant metastasis in patients with GC, suggest-
ing that low levels of NPM1 protein expression may be a
marker of poor prognosis in GC if validated in larger
clinical study sets. Reduced NPM1 protein level was pre-
viously associated with poor outcome in some subtypes
of breast cancer [30]. On the other hand, NPM1 overex-
pression was associated with the presence of distant
Figure 2 Immunohistochemical analysis of NPM1 in gastric samples. (A) NPM1 staining in normal gastric mucosa (400×); (B) cytoplasmatic
NPM1 staining in parietal cells (400×); (C) NPM1 immunoreactivity in inflammatory cells (400×); (D) NPM1 staining in intestinal metaplastic cells
(400×); (E) minimal NPM1 staining in a poorly differentiated tumor (400×); (F) weak NPM1 staining in a poorly differentiated tumor (400×); (G)
moderate NPM1 staining in a moderately differentiated tumor (400×); (H) moderate NPM1 staining in a diffuse-type tumor (400×).
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Table 2 Immunohistochemistry analysis in gastric tumors
Case Histological subtype Differentiation Stage % of stained tumor cells Location Intensity of staining Score
1 Intestinal-type Moderately differentiated 1 60% Nucleus Moderate 2
Nucleolus Moderate 2
2 Intestinal-type Poorly differentiated 4 < 10% Nucleus Weak 0
Nucleolus Moderate 0
3 Intestinal-type Moderately differentiated 4 40% Nucleus Weak 1
Nucleolus Moderate 2
4 Intestinal-type Moderately differentiated 1 20% Nucleus Moderate 2
Nucleolus Moderate 2
5* Intestinal-type Moderately differentiated 1 40% Nucleus Weak 1
Nucleolus Moderate 2
6 Intestinal-type Poorly differentiated 3 < 10% Nucleus Weak 0
Nucleolus Weak 0
7 Intestinal-type Moderately differentiated 1 < 10% Nucleus Weak 0
Nucleolus Weak 0
8 Intestinal-type Moderately differentiated 3 < 10% Nucleus Weak 0
Nucleolus Weak 0
9 Intestinal-type Moderately differentiated 4 20% Nucleus Weak 1
Nucleolus Moderate 2
10 Intestinal-type Moderately differentiated 2 < 10% Nucleus Weak 0
Nucleolus Weak 0
11 Intestinal-type Poorly differentiated 3 40% Nucleus Weak 1
Nucleolus Moderate 2
12 Diffuse-type Not applied 3 20% Nucleus Moderate 2
Nucleolus Moderate 2
*This patient presented strong cytoplasmatic immunoreactivity in normal parietal cells (score = 3).
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depend on cellular and genetic context. The interaction
between NPM1 and MYC may be one of the pathways
by which the loss of NPM1 contributes to the develop-
ment of metastasis. The lack of a functional NPM1 was
previously associated with increased levels of MYC [32].
MYC is a key oncogene in gastric carcinogenesis (see re-
view [33]), and the overexpression or amplification of
the MYC locus was previously reported in GC samples
and preneoplastic gastric lesions [34-41]. In our popula-
tion, MYC overexpression was previously associated
with the presence of distant metastasis [42]. Moreover,
the three tumors of patients with distant metastasis pre-
sented MYC immunoreactivity (data not shown).
Here, we observed that NPM1 presented nuclear and
nucleolar location. Previous studies showed that NPM1
is a predominantly nucleolar protein, however, a fraction
can also be detected in the nucleoplasm (see review
[43]). Although the sample size is small, an inverse cor-
relation between nucleoli immunoreactivity and the pro-
tein expression (total expression) by Western blot was
observed. This finding may be in part to the key role ofNPM1 in ribosome biogenesis. In both subcellular com-
partments, the NPM1 immunoreactivity presented a large
inter- and intra-tumor heterogeneity. The NPM1 expres-
sion heterogeneity in GC cells may complicate the devel-
opment of diagnostic tests or treatments targeting the
NPM1. Efforts to pharmacologically target NPM1 for can-
cer therapy might be difficult, due to the fact that its func-
tion is likely to be tightly regulated to avoid the possibly
detrimental consequences of its decreased or increased
function [3].
The NPM1 immunoreactivity was also heterogeneous
in intestinal metaplastic, gastritis and inflammatory cells,
which are commonly observed in GC patients. NPM1
may also act as an alarmin in the immune system [44].
In macrophages, NPM1 negatively regulates cytokine
and chemokine gene expression and their secretion [45].
We hypothesized that the NPM1 expression in tumor
cells is modulated in response to microenvironmental
stimuli.
We also demonstrated that NPM1 mRNA expression
was inversely correlated with protein expression, which
suggests that post-translational mechanisms may be
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studies demonstrated that NPM1 protein is modified by
ubiquitylation [46-49], which may lead to its depletion
despite the elevated mRNA transcription. Proteins make
up the cellular machinery and play major roles in most
biological processes. Thus, direct assessment of protein
levels may often be more informative of the cellular state
than analysis of mRNA levels [50]. Protein expression is
subject to complex control and is only partly determined
by accumulation and degradation of the corresponding
mRNAs [51,52]; it is suggested that 20–60% of the vari-
ation in steady-state protein abundances is attributable
to mRNA levels [53]. It has been speculated that tran-
scriptional bursts, observed to increase variance in
mRNA abundance, may be buffered by long protein
half-lives [54].
In addition, NPM1 mRNA expression did not differ
between tumors and non-neoplastic samples. Although
approximately 45% of tumors presented reduced mRNA
expression, about 27% of GC presented more than 1.5-
fold increased expression compared to matched non-
neoplastic tissue. To our knowledge, only two previous
studies evaluated NPM1 mRNA in gastric tumors by
Northern blot. Tanaka et al. [21] reported that 2 of 3 tu-
mors presented hybridization with NPM1 probe, which
was not observed in any of the non-neoplastic samples.
You et al. [22] demonstrated that 6 of 7 GC samples pre-
sented increased expression compared to non-neoplastic
gastric tissue. However, the present study used RT-qPCR,
the most sensitive method for detection and quantification
of mRNA expression. Additionally, we evaluated a larger
number of samples, which may better reflect the hetero-
geneity of gastric tumors.
Moreover, we observed that intestinal-type GC pre-
sented higher mRNA levels than diffuse-type GC, con-
firming that these two histological GC subtypes follow
different genetic pathways and may be two distinct en-
tities [55]. Although NPM1 mRNA seems to be higher
in intestinal-type GC, this subtype showed relatively
lower levels of NPM1 protein expression compared to
the non-neoplastic samples, which reinforces the in-
verse correlation between NPM1 protein and mRNA
expression.Conclusions
We demonstrated that NPM1 down-regulation may have
a role in gastric carcinogenesis, especially in intestinal-
type GC and in tumors from patients with distant me-
tastasis. However, NPM1 expression presented a large
inter- and intra-tumor heterogeneity, which might com-
plicate the development of diagnostic tests or treatments
targeting the NPM1. On the other hand, NPM1 protein
down-regulation may help in the selection of anticancertreatment strategies based on a better understanding of
the pathways deregulated in GC.
Abbreviations
GC: Gastric cancer; NPM1: Nucleophosmin 1; CHAPS: 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate; DTT: Dithiothreitol;
PVDF: Polyvinylidene difluoride; ACTB: β-Actin; qPCR: quantitative PCR;
RT-qPCR: Reverse transcription quantitative PCR; RQ: Relative quantification;
SD: Standard deviation; ARF: Cyclin-dependent kinase inhibitor 2A (CDKNA2)
alternate reading frame protein; MDM2: E3 ubiquitin-protein ligase.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MFL, RC, RRB and MACS conceived and designed the experiments. MFL was
involved in literature search, genetic and statistical analysis. TKFM, PDRC and
MCM were involved in immunohistochemistry analysis. MFL and DQC were
involved in data collection. SD was responsible for pathology analysis. PPA
was responsible by samples collection. MFL wrote the first draft of the
manuscript. All authors listed have contributed to all subsequent drafts, and
have approved the final manuscript.
Acknowledgements
Supported by Conselho Nacional de Desenvolvimento Científico e
Tecnológico (CNPq; RC, MACS and RRB) and Fundação de Amparo à
Pesquisa do Estado de São Paulo (FAPESP; MFL, DQC and PDRC) as grants
and fellowship awards. The authors are thankful to Sueli Nonogaki from
Adolfo Lutz (São Paulo, SP, Brazil) for the technical support in the
immunohistochemistry analyses.
Author details
1Genetics Division, Department of Morphology and Genetic, Federal
University of São Paulo, R. Botucatu, 740, São Paulo, SP CEP 04023-900, Brazil.
2Department of Orthopedics and Traumatology, Federal University of São
Paulo, São Paulo, SP 04038-031, Brazil. 3Experimental Oncology Laboratory,
Department of Radiology, School of Medicine, University of São Paulo, São
Paulo, SP 01246-903, Brazil. 4Center for Translational Oncology, São Paulo
State Cancer Institute, São Paulo, SP 01246-000, Brazil. 5Research Center of
Oncology, João de Barros Barreto University Hospital, Federal University of
Pará, Belém, PA 60673-000, Brazil. 6Human Cytogenetics Laboratory, Institute
of Biological Sciences, Federal University of Pará, Belém, PA 66073-000, Brazil.
Received: 5 March 2013 Accepted: 31 December 2013
Published: 10 January 2014
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61(2):69–90.
2. Leal MF, Chung J, Calcagno DQ, Assumpcao PP, Demachki S, da Silva ID,
Chammas R, Burbano RR, de Arruda Cardoso Smith M: Differential
proteomic analysis of noncardia gastric cancer from individuals of
northern Brazil. PLoS One 2012, 7(7):e42255.
3. Grisendi S, Mecucci C, Falini B, Pandolfi PP: Nucleophosmin and cancer.
Nat Rev Cancer 2006, 6(7):493–505.
4. Szebeni A, Olson MO: Nucleolar protein B23 has molecular chaperone
activities. Protein Sci 1999, 8(4):905–912.
5. Okuwaki M, Tsujimoto M, Nagata K: The RNA binding activity of a
ribosome biogenesis factor, nucleophosmin/B23, is modulated by
phosphorylation with a cell cycle-dependent kinase and by association
with its subtype. Mol Biol Cell 2002, 13(6):2016–2030.
6. Okuda M: The role of nucleophosmin in centrosome duplication.
Oncogene 2002, 21(40):6170–6174.
7. Tarapore P, Okuda M, Fukasawa K: A mammalian in vitro centriole
duplication system: evidence for involvement of CDK2/cyclin E and
nucleophosmin/B23 in centrosome duplication. Cell Cycle 2002, 1(1):75–81.
8. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, Pandolfi PP:
Role of nucleophosmin in embryonic development and tumorigenesis.
Nature 2005, 437(7055):147–153.
9. Gimenez M, Souza VC, Izumi C, Barbieri MR, Chammas R, Oba-Shinjo SM,
Uno M, Marie SK, Rosa JC: Proteomic analysis of low- to high-grade
Leal et al. BMC Gastroenterology 2014, 14:9 Page 9 of 10
http://www.biomedcentral.com/1471-230X/14/9astrocytomas reveals an alteration of the expression level of raf kinase
inhibitor protein and nucleophosmin. Proteomics 2010, 10(15):2812–2821.
10. Nozawa Y, Van Belzen N, Van der Made AC, Dinjens WN, Bosman FT:
Expression of nucleophosmin/B23 in normal and neoplastic colorectal
mucosa. J Pathol 1996, 178(1):48–52.
11. Yun JP, Miao J, Chen GG, Tian QH, Zhang CQ, Xiang J, Fu J, Lai PB:
Increased expression of nucleophosmin/B23 in hepatocellular carcinoma
and correlation with clinicopathological parameters. Br J Cancer 2007,
96(3):477–484.
12. Tsui KH, Cheng AJ, Chang PL, Pan TL, Yung BY: Association of
nucleophosmin/B23 mRNA expression with clinical outcome in patients
with bladder carcinoma. Urology 2004, 64(4):839–844.
13. Skaar TC, Prasad SC, Sharareh S, Lippman ME, Brunner N, Clarke R: Two-
dimensional gel electrophoresis analyses identify nucleophosmin as an
estrogen regulated protein associated with acquired estrogen-
independence in human breast cancer cells. J Steroid Biochem Mol Biol
1998, 67(5–6):391–402.
14. Shields LB, Gercel-Taylor C, Yashar CM, Wan TC, Katsanis WA, Spinnato JA,
Taylor DD: Induction of immune responses to ovarian tumor antigens by
multiparity. J Soc Gynecol Investig 1997, 4(6):298–304.
15. Subong EN, Shue MJ, Epstein JI, Briggman JV, Chan PK, Partin AW: Monoclonal
antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes
nucleophosmin/B23. Prostate 1999, 39(4):298–304.
16. Qian Z, Joslin JM, Tennant TR, Reshmi SC, Young DJ, Stoddart A, Larson RA,
Le Beau MM: Cytogenetic and genetic pathways in therapy-related acute
myeloid leukemia. Chem Biol Interact 2010, 184(1–2):50–57.
17. Naoe T, Suzuki T, Kiyoi H, Urano T: Nucleophosmin: a versatile molecule
associated with hematological malignancies. Cancer Sci 2006,
97(10):963–969.
18. Mendes-da-Silva P, Moreira A, Duro-da-Costa J, Matias D, Monteiro C:
Frequent loss of heterozygosity on chromosome 5 in non-small cell lung
carcinoma. Mol Pathol 2000, 53(4):184–187.
19. Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, Haferlach T: Acute
myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct
entity? Blood 2011, 117(4):1109–1120.
20. Zeller KI, Haggerty TJ, Barrett JF, Guo Q, Wonsey DR, Dang CV:
Characterization of nucleophosmin (B23) as a Myc target by scanning
chromatin immunoprecipitation. J Biol Chem 2001, 276(51):48285–48291.
21. Tanaka M, Sasaki H, Kino I, Sugimura T, Terada M: Genes preferentially
expressed in embryo stomach are predominantly expressed in gastric
cancer. Cancer Res 1992, 52(12):3372–3377.
22. You BJ, Huang IJ, Liu WH, Hung YB, Chang JH, Yung BY: Decrease in
nucleophosmin/B23 mRNA and telomerase activity during
indomethacin-induced apoptosis of gastric KATO-III cancer cells.
Naunyn Schmiedebergs Arch Pharmacol 1999, 360(6):683–690.
23. Lauren P: The two histological main types of gastric carcinoma: diffuse
and so-called intestinal-type carcinoma. an attempt at a histo-clinical
classification. Acta Pathol Microbiol Scand 1965, 64:31–49.
24. Sobin LH, Gopodarowicz MK, Wittekind C: TNM Classification of Malignant
Tumors. 7th edition. Oxford: Wiley-Blackwell; 2009.
25. Clayton CL, Kleanthous H, Coates PJ, Morgan DD, Tabaqchali S: Sensitive
detection of Helicobacter pylori by using polymerase chain reaction.
J Clin Microbiol 1992, 30(1):192–200.
26. Lobo Gatti L, Agostinho Jn F, De Labio R, Balbo Piason F, Carlos Da Silva
L, Fagundez De Queiroz V, Peres CA, Barbieri D, De Arruda Cardoso
Smith M, Marques Payao SL: Helicobacter pylori and cagA and vacA
gene status in children from Brazil with chronic gastritis. Clin Exp Med
2003, 3(3):166–172.
27. Pfaffl MW: A new mathematical model for relative quantification in
real-time RT-PCR. Nucleic Acids Res 2001, 29(9):e45.
28. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA,
Grosveld G, Sherr CJ: Tumor suppression at the mouse INK4a locus
mediated by the alternative reading frame product p19ARF. Cell 1997,
91(5):649–659.
29. Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ: N-terminal
polyubiquitination and degradation of the Arf tumor suppressor.
Genes Dev 2004, 18(15):1862–1874.
30. Karhemo PR, Rivinoja A, Lundin J, Hyvonen M, Chernenko A, Lammi J, Sihto H,
Lundin M, Heikkila P, Joensuu H, et al: An extensive tumor array analysis
supports tumor suppressive role for nucleophosmin in breast cancer.
Am J Pathol 2011, 179(2):1004–1014.31. Liu Y, Zhang F, Zhang XF, Qi LS, Yang L, Guo H, Zhang N: Expression of
nucleophosmin/NPM1 correlates with migration and invasiveness of
colon cancer cells. J Biomed Sci 2012, 19:53.
32. Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG, Colombo E: Nucleophosmin
and its AML-associated mutant regulate c-Myc turnover through Fbw7
gamma. J Cell Biol 2008, 182(1):19–26.
33. Calcagno DQ, Leal MF, Assumpcao PP, Smith MA, Burbano RR: MYC and
gastric adenocarcinoma carcinogenesis. World J Gastroenterol 2008,
14(39):5962–5968.
34. Leal MF, Calcagno DQ, Khayat AS, Silva TC, Muniz JA, Assumpcao PP, de
Arruda Cardoso Smith M, Burbano RR: hTERT and TP53 deregulation in
intestinal-type gastric carcinogenesis in non-human primates. Clin Exp
Med 2013, 13(3):221–224.
35. Assumpcao PP, Ishak G, Chen ES, Takeno SS, Leal MF, Guimaraes AC,
Calcagno DQ, Khayat AS, Demachki S, Smith Mde A, et al: Numerical
aberrations of chromosome 8 detected by conventional cytogenetics
and fluorescence in situ hybridization in individuals from northern Brazil
with gastric adenocarcinoma. Cancer Genet Cytogenet 2006, 169(1):45–49.
36. Burbano RR, Assumpcao PP, Leal MF, Calcagno DQ, Guimaraes AC, Khayat
AS, Takeno SS, Chen ES, De Arruda Cardoso SM: C-MYC locus amplification
as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH
study in Brazil. Anticancer Res 2006, 26(4B):2909–2914.
37. Calcagno DQ, Guimaraes AC, Leal MF, Seabra AD, Khayat AS, Pontes TB,
Assumpcao PP, De Arruda Cardoso SM, Burbano RR: MYC insertions in
diffuse-type gastric adenocarcinoma. Anticancer Res 2009, 29(7):2479–2483.
38. Calcagno DQ, Leal MF, Demachki S, Araujo MT, Freitas FW, Oliveira e Souza
D, Assumpcao PP, Ishak G, de Arruda Cardoso Smith M, Burbano RR: MYC
in gastric carcinoma and intestinal metaplasia of young adults.
Cancer Genet Cytogenet 2010, 202(1):63–66.
39. Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S,
Assumpcao PP, Faria MH, Rabenhorst SH, Ferreira MV, et al: Interrelationship
between chromosome 8 aneuploidy, C-MYC amplification and increased
expression in individuals from northern Brazil with gastric adenocarcinoma.
World J Gastroenterol 2006, 12(38):6207–6211.
40. Calcagno DQ, Leal MF, Taken SS, Assumpcao PP, Demachki S, Smith Mde A,
Burbano RR: Aneuploidy of chromosome 8 and C-MYC amplification in
individuals from northern Brazil with gastric adenocarcinoma. Anticancer
Res 2005, 25(6B):4069–4074.
41. Costa Raiol LC, Figueira Silva EC, Mendes Da Fonseca D, Leal MF, Guimaraes
AC, Calcagno DQ, Khayat AS, Assumpcao PP, De Arruda Cardoso Smith M,
Burbano RR: Interrelationship between MYC gene numerical aberrations
and protein expression in individuals from northern Brazil with early
gastric adenocarcinoma. Cancer Genet Cytogenet 2008, 181(1):31–35.
42. Rosal-Texeira C, Leal MF, Calcagno DQ, Sozinho EKC, Borges BN,
Montenegro RC, Santos AKR, Santos SEB, Ribeiro HF, Assumpção PP, et al:
MYC deregulation in gastric cancer and its clinicopathological
implications. PLoS One 2013. in press.
43. Lindstrom MS: NPM1/B23: a multifunctional chaperone in ribosome
biogenesis and chromatin remodeling. Biochem Res Int 2011, 2011:195209.
44. Nawa Y, Kawahara K, Tancharoen S, Meng X, Sameshima H, Ito T, Masuda Y,
Imaizumi H, Hashiguchi T, Maruyama I: Nucleophosmin may act as an
alarmin: implications for severe sepsis. J Leukoc Biol 2009, 86(3):645–653.
45. Guery L, Benikhlef N, Gautier T, Paul C, Jego G, Dufour E, Jacquel A, Cally R,
Manoury B, Vanden Berghe T, et al: Fine-tuning nucleophosmin in
macrophage differentiation and activation. Blood 2011, 118(17):4694–4704.
46. Enomoto T, Lindstrom MS, Jin A, Ke H, Zhang Y: Essential role of the B23/
NPM core domain in regulating ARF binding and B23 stability. J Biol
Chem 2006, 281(27):18463–18472.
47. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, Zhang Y: Tumor
suppressor ARF degrades B23, a nucleolar protein involved in ribosome
biogenesis and cell proliferation. Mol Cell 2003, 12(5):1151–1164.
48. Endo A, Matsumoto M, Inada T, Yamamoto A, Nakayama KI, Kitamura N,
Komada M: Nucleolar structure and function are regulated by the
deubiquitylating enzyme USP36. J Cell Sci 2009, 122(Pt 5):678–686.
49. Sato K, Hayami R, Wu W, Nishikawa T, Nishikawa H, Okuda Y, Ogata H,
Fukuda M, Ohta T: Nucleophosmin/B23 is a candidate substrate for the
BRCA1-BARD1 ubiquitin ligase. J Biol Chem 2004, 279(30):30919–30922.
50. Laurent JM, Vogel C, Kwon T, Craig SA, Boutz DR, Huse HK, Nozue K,
Walia H, Whiteley M, Ronald PC, et al: Protein abundances are more
conserved than mRNA abundances across diverse taxa. Proteomics
2010, 10(23):4209–4212.
Leal et al. BMC Gastroenterology 2014, 14:9 Page 10 of 10
http://www.biomedcentral.com/1471-230X/14/951. Lu P, Vogel C, Wang R, Yao X, Marcotte EM: Absolute protein expression
profiling estimates the relative contributions of transcriptional and
translational regulation. Nat Biotechnol 2007, 25(1):117–124.
52. Anderson L, Seilhamer J: A comparison of selected mRNA and protein
abundances in human liver. Electrophoresis 1997, 18(3–4):533–537.
53. de Sousa AR, Penalva LO, Marcotte EM, Vogel C: Global signatures of
protein and mRNA expression levels. Mol Biosyst 2009, 5(12):1512–1526.
54. Raj A, Peskin CS, Tranchina D, Vargas DY, Tyagi S: Stochastic mRNA
synthesis in mammalian cells. PLoS Biol 2006, 4(10):e309.
55. Tahara E: Genetic pathways of two types of gastric cancer. IARC Sci Publ
2004, 157:327–349.
doi:10.1186/1471-230X-14-9
Cite this article as: Leal et al.: Deregulated expression of Nucleophosmin
1 in gastric cancer and its clinicopathological implications. BMC
Gastroenterology 2014 14:9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
